An observational study in Critical Illness and Acute Kidney Injury, sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital · Observational
Among 90 studies in Acute Kidney Injury with a site in Turkey — 22 open to participants now, 23 under way, none of them phase 3. Acute Kidney Injury · Turkey.
Among the 90 studies in Acute Kidney Injury with a site in Turkey, this one is the 27th largest by enrollment of the 73 observational ones that give a count, is one of 18 that started in 2026, is one of 73 observational ones, and was the 84th registered.
1,691 studies on the registry are indexed under Acute Kidney Injury; 394 are open to participants now.
Browse Acute Kidney Injury studies →22 of the 90 studies in Acute Kidney Injury with a site in Turkey are open now. Recruiting first, the newest first:
Namik Kemal University · Sites in Turkey
Ages 18+
AstraZeneca · Sites in Turkey, United States, Argentina and 11 more countries
Ages 18–80
Osman Sila Aydin · Sites in Turkey
Ages 18+
Istanbul University - Cerrahpasa · Sites in Turkey
Ages 18–80
Gaziosmanpasa Research and Education Hospital · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 230 Acute Kidney Injury studies recruiting now, 161 (70%) set no upper age limit and 36 (16%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 18 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is close to the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Median enrollment 108 across the 17 interventional studies, 130 across the 73 observational. Of the 60 that completed or were terminated, 2 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 90 have an industry lead sponsor. The 10 most frequent:
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital is the lead sponsor of 75 studies on the registry; 18 are open to participants now.
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital has 1 study filed under Acute Kidney Injury — fewer than ten, so there is no comparison to draw.
12 of the studies in Acute Kidney Injury with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
| NCT07635160Istanbul University - CerrahpasaAssessment of Renal Perfusion Using Ultrasound and Near-Infrared Spectroscopy in Patients Undergoing Minimally Invasive Abdominal Surgery | 2027-01-07 |
| NCT07918742Istanbul University - CerrahpasaDiastolic Shock Index for Predicting Hemodynamic Instability During Continuous Renal Replacement Therapy | 2027-01-31 |
| NCT07704242Medipol UniversityEarly Kidney Injury Biomarkers in Gynecologic Laparoscopic Surgery | 2027-02-01 |
| NCT07215702AstraZenecaA Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury. | 2027-02-11 |
Add all 12 to your calendar (.ics) → With an account.
Among the 90 studies in Acute Kidney Injury with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this retrospective observational study is to evaluate how long continuous renal replacement therapy (CRRT) circuits remain in use in adult intensive care unit patients and to describe how CRRT pressure measurements change over time. The main questions it aims to answer are:
Are higher maximum and mean transmembrane pressure (TMP) values associated with longer CRRT circuit lifespan? Do time-normalized pressure trajectories and cumulative TMP burden differ between circuits with different lifespans? Do access pressure patterns influence the relationship between pressure measurements and circuit lifespan? Researchers will analyze archived CRRT device log files, including access pressure, filter pressure, effluent pressure, return pressure, and TMP measurements. No additional procedures, interventions, or study visits will be required. No directly identifiable patient information will be included in the analytical dataset.
1,691 studies on the registry are indexed under Acute Kidney Injury; 394 are open to participants now.
This study's enrollment of 162 is close to the median of 160 across 814 observational studies indexed under Acute Kidney Injury.
Browse Acute Kidney Injury studies →Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital is the lead sponsor of 75 studies on the registry; 18 are open to participants now.
Compared within Acute Kidney Injury, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
The study population consists of adult intensive care unit (ICU) patients who underwent continuous renal replacement therapy (CRRT) using the Prismaflex platform. Archived device log files (LOX format) generated during routine clinical care were evaluated. The unit of analysis was the individual CRRT session rather than the patient, as device logs were structured at the treatment-session level and patient-level linkage was not consistently available. Eligible sessions had a minimum runtime of 1 hour and at least 60 valid, chronologically ordered pressure recordings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
CRRT sessions with a circuit lifespan of less than 12 hours, defined as the time between the first and last valid pressure recording in the device log. No intervention was assigned.
Other: Archived CRRT Device Log Data
CRRT sessions with a circuit lifespan of at least 12 hours but less than 24 hours, defined as the time between the first and last valid pressure recording in the device log. No intervention was assigned.
Other: Archived CRRT Device Log Data
CRRT sessions with a circuit lifespan of at least 24 hours but less than 48 hours, defined as the time between the first and last valid pressure recording in the device log. No intervention was assigned.
Other: Archived CRRT Device Log Data
CRRT sessions with a circuit lifespan of 48 hours or longer, defined as the time between the first and last valid pressure recording in the device log. No intervention was assigned.
Other: Archived CRRT Device Log Data
This observational study involves no assigned intervention, treatment, device use, or change in clinical care. The study analyzes archived pressure recordings from CRRT device log files generated during routine clinical care. The analyzed variables include access pressure, filter pressure, effluent pressure, return pressure, and transmembrane pressure. CRRT circuit lifespan is evaluated retrospectively according to the time between the first and last valid pressure recording. No additional procedures or study-related interventions are performed.
Maximum Transmembrane Pressure Across CRRT Circuit Lifespan Categories
To compare maximum transmembrane pressure values among CRRT sessions grouped by circuit lifespan: less than 12 hours, 12 to less than 24 hours, 24 to less than 48 hours, and 48 hours or longer.
Time frame: From the first to the last valid pressure recording of each CRRT session
Initial 6-hour TMP slope
The initial 6-hour transmembrane pressure (TMP) slope will be calculated from the time-stamped TMP measurements obtained during the first 6 hours of each CRRT session. It will be expressed in mmHg per hour and will be evaluated as a secondary pressure-dynamics measure in relation to CRRT circuit lifespan and lifespan categories. Sessions without sufficient pressure data during the initial 6-hour period will be excluded from this specific analysis.
Time frame: During the first 6 hours of each CRRT session
Plan to share: No — Individual participant data will not be shared with other researchers. This retrospective study uses archived CRRT device log files, and patient-level linkage was not consistently available. The analytical dataset does not include directly identifiable patient information; however, the underlying device logs and study dataset will not be made publicly available because of institutional data-protection requirements and the terms of the ethics approval. Aggregate results will be reported in the publication.
No publications or documents are linked to this record.
Ran from Sep 2026 to primary completion in Sep 2026, 0 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital